Firm believes its Q1 shipments surpassed ADAC’sThe nuclear medicine group of Siemens Medical Systems continues its remarkable rebound, powered by sales of its variable-angle E.Cam gamma camera. The Hoffman Estates, IL, division believes that
Firm believes its Q1 shipments surpassed ADACs
The nuclear medicine group of Siemens Medical Systems continues its remarkable rebound, powered by sales of its variable-angle E.Cam gamma camera. The Hoffman Estates, IL, division believes that it reclaimed the title of worlds largest gamma camera manufacturer in the first quarter of 1998, besting long-time market leader ADAC Laboratories.
At its peak in the late 1980s, Siemens was the largest gamma camera firm, with a global market share in the high 30% range. The companys trajectory was interrupted in the mid-1990s, however, when it failed to develop a variable-angle dual-head gamma camera as quickly as some of its competitors, namely Milpitas, CA-based ADAC. Siemens has seen its fortunes improve dramatically since the debut of E.Cam at the Society of Nuclear Medicine conference in 1996, however, and last year the company reported a dramatic increase in market share (SCAN 10/1/97).
The companys momentum has continued into 1998, according to Paul Ottoson, marketing manager of nuclear medicine. Siemens is enjoying a 90% increase in order volume, with more than 300 E.Cam units shipped in the past year. In addition, the company believes that its first-quarter worldwide sales of SPECT cameras surpassed those of ADAC, a claim the company makes based on comparing its own internal numbers with those of ADACs first-quarter results. Siemens included sales of ADACs Molecular Coincidence Detection (MCD) products in the analysis.
At this years SNM meeting in Toronto, Siemens will demonstrate its latest R&D work on keeping E.Cam competitive, with a focus on clinical trials under way for coincidence detection and attenuation correction. One highlight will be the divisions development of new crystal combinations designed to enable a single camera to image both high-energy and low-energy radioisotopes with optimal resolution.
Early research in this area conducted by Siemens and R&D partner CTI of Knoxville, TN, concentrated on a hybrid crystal for both PET and SPECT studies. The crystal was made by pairing LSO, which carries a density and photon-stopping power similar to BGO, the detector material used in PET cameras, with YSO, a compound used for low-energy imaging. Siemens and CTI have since modified the approach, however, by combining LSO with sodium iodide rather than YSO. The company cites YSOs disadvantages relative to sodium iodide, such as its higher production cost, inferior energy resolution, and relatively unknown performance, as the reason for the switch.
Weve made some technical breakthroughs that allow us to use sodium iodide rather than depending on YSO, Ottoson said. Were able to segment sodium iodide, as we segment the LSO, to have block detectors, much like a PET scanner. One of our challenges was to get enough light out of the sodium iodide, and now weve developed a reflective material that allows us to do that.
Siemens intends to develop a hybrid PET/SPECT device by incorporating the LSO/sodium iodide detectors into an E.Cam gantry. With a 510(k) application for the device already submitted to the Food and Drug Administration, the company expects clearance by the SNM conference, and plans to ship the first alpha units in early fall.
As part of a small group of imaging vendors that offer both PET and SPECT cameras in their product lines, Siemens finds itself in a unique position in the rush to develop high-energy imaging technology: It needs to protect its PET market while staying current in SPECT. Siemens believes that there will always be a role for PET technology, however.
We believe that coincidence will play some role in positron imaging, that it will have some applications for different indications, but certainly not all of the things that PET can doit will never be a true PET device, Ottoson said.
Siemens will introduce other E.Cam extensions at the SNM meeting, including imaging pallets geared toward specific indications such as scintimammography and pediatric imaging. Siemens will display Apples new G3 computer platform for its Icon workstation, and the company is also working on 76 acquisitions and dynamic SPECT for release later this year.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.